NUWE
Nuwellis, Inc.2.2100
+0.0300+1.38%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details Rendiatek's AKI monitoring fit
Q&A unpacked Nuwellis' refocus drivers—a product recall spurring KDI manufacturing shift, EU exit amid losses, and REVERSE-HF trial axed to save $3 million—beyond prepared remarks' high-level changes. CEO detailed Rendiatek's critical care hook: bedside urine output monitoring post-heart-lung bypass, eyeing electrolyte add-ons for AKI in 60% of patients. Sales team holds steady at 24, laser-focused on critical care utilization in existing accounts. Rendiatek integration promises deeper penetration there. Management stayed crisp on execution, no hedges. Investors watch critical care ramp and portfolio relaunch.
Key Stats
Market Cap
1.99MP/E (TTM)
-Basic EPS (TTM)
-250.62Dividend Yield
0%Recent Filings
10-K
FY2025 results
Nuwellis posted FY2025 net sales of $8.3M, down 5% y/y amid a voluntary blood circuit recall and manufacturing transition, yet pediatrics held steady at 40% of revenue while critical care contributed 32%. Q4 momentum faltered with revenue deceleration and operating losses widening to $17.5M annually, driven by $10.6M in financing expenses from warrant liabilities. Cash burned to $1.2M by year-end, sufficient only through Q2 2026; no dividends or buybacks amid going concern warnings. Nasdaq compliance held via reverse splits. Single-product reliance risks quarterly sales volatility.
8-K
Q4 revenue up 4%, margins soar
Nuwellis reported Q4 2025 revenue of $2.4M, up 4% year-over-year on 208% U.S. console sales surge and Heart Failure/Pediatrics growth, with gross margin jumping to 68.2% from 58.4%. Full-year revenue fell 5% to $8.3M, net loss hit $17.5M amid $6.4M warrant expense; cash ended at $1.2M, debt-free. Q4 margins improved sharply. Post-period, $5M capital raise and Rendiatech acquisition deal bolster cardiorenal push.
8-K
Board expands with experts
Nuwellis expanded its board from five to seven members on February 24, 2026, appointing independent directors Martin J. Emerson and David A. McDonald, both financial experts joining key committees. Emerson brings medtech CEO experience; McDonald, capital markets savvy. Board bolsters operational discipline. Separately, E.F. Hutton sued February 11 over alleged placement agent breach; Nuwellis will defend vigorously, outcome uncertain.
8-K
Nuwellis raises $5M, buys Rendiatech
Nuwellis raised ~$5.1M via private placement of pre-funded warrants and common warrants to an institutional investor, plus $2M from warrant inducement exercises, funding working capital. Signed Rendiatech acquisition for Clarity RMS/Prime kidney monitors—$125K cash now, 150K shares, options, plus $375K deferred and 9% sales royalty up to $2M. Named Carisa Schultz CFO effective Feb 2. Fresh capital fuels cardiorenal push.
EMED
Electromedical Technologies, In
0.00+0.00
ENOV
Enovis Corporation
26.07-0.47
EW
Edwards Lifesciences Corporatio
85.32+1.94
NAOV
NanoVibronix, Inc.
4.02-0.29
NEPH
Nephros, Inc.
4.85-0.01
NSYS
Nortech Systems Incorporated
7.17+0.18
NUMD
Nu-Med Plus Inc.
0.02-0.01
NXL
Nexalin Technology, Inc.
0.81-0.01
SNWV
SANUWAVE Health, Inc.
31.46-0.18
ZYXI
Zynex, Inc.
0.34-0.32